Caribou Biosciences (CRBU)
(Delayed Data from NSDQ)
$2.49 USD
+0.05 (2.05%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.48 -0.01 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Caribou Biosciences, Inc. [CRBU]
Reports for Purchase
Showing records 1 - 18 ( 18 total )
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CB-010''s Efficacy Declines; Pivotal Trial Pushed Back at Least 6 Months; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Updated ANTLER Trial Results at ASCO; 1Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Dose Expansion Data Expected for CB-010 Imminently; 4Q23 Financials; Modulating PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Trial Design Aligned in 2L LBCL With the FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CB-010 Initial Dose-Expansion Data in 1H24; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
FDA Clears CB-012 to Enter Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Collaboration Termination Non-Impactful, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CB-010 FDA Feedback in 2L LBCL by Year-End; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Updated ANTLER Data; Pfizer Backing CB-011 CAR-T; Lowering PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Updated ANTLER Data by Year-End; 1Q23 Financial Results; Adjusting PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ANTLER Trial Advancing; Financial Results Reported; Modulating PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Myeloma Landscape - CD38, BCMA, GPRC5D, and FcRH5 (Version 1.0)
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Updated ANTLER Data by YE; CD19-Targeted Competitor Data Imminent; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CB-010 Complete Response Rate Rises; 2Q22 Financials; Adjusting PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We Continue to View CB-010 Favorably; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
CB-010 Demonstrates Encouraging ORR at Dose Level 1; 1Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
"Natural Born Killers" An Update in NK Cell Therapy
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Caribou Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Creating CRISPR-Charged Cellular Therapies; Initiating at Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
|